Damora Therapeutics (DMRA) Preferred Stock Liabilities (2019 - 2026)

Damora Therapeutics' Preferred Stock Liabilities history runs 5 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Preferred Stock Liabilities fell 1.4% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 1.4% YoY) and the FY2025 annual result came in at $1.3 million, down 1.4% from the prior year.
• Preferred Stock Liabilities was $1.3 million for Q1 2026 at Damora Therapeutics, roughly flat from $1.3 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $1.4 million in Q4 2024 and bottomed at $1.3 million in Q2 2025.
• A 3-year average of $1.3 million and a median of $1.3 million in 2025 frame the typical range for Preferred Stock Liabilities.
• Peak annual rise in Preferred Stock Liabilities reached 1.4% in 2025, while the deepest fall reached 1.4% in 2025.
• Damora Therapeutics' Preferred Stock Liabilities stood at $1.4 million in 2024, then decreased by 1.4% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Business Quant data shows DMRA's Preferred Stock Liabilities at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.